Anaplastic Large Cell Lymphoma (DBCOND0028602)

Identifiers

Synonyms

ALCL / Anaplastic large cell lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large-cell lymphoma / Anaplastic large cell lymphoma, ALK-positive / Large cell anaplastic lymphoma T cell and Null cell type (disorder) / Anaplastic large cell lymphoma, T cell and Null cell type (morphologic abnormality)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06120504	A Safety Study of SGN-35T in Adults With Advanced Cancers	No drug interventions	treatment	1	recruiting
NCT06254495	A Safety Study of SGN-35C in Adults With Advanced Cancers	No drug interventions	treatment	1	recruiting
NCT01748721	MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Ontuxizumab	treatment	1	completed
NCT00649584	A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies	Brentuximab vedotin Gemcitabine	treatment	1	terminated
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Cyclophosphamide Cyclosporine Filgrastim Fludarabine Mycophenolate mofetil Mycophenolic acid Treosulfan	treatment	2	recruiting
NCT01116154	Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Lenalidomide Vorinostat	treatment	1	terminated
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT03493451	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms	Tislelizumab	treatment	2	completed
NCT03397953	Vinorelbine for Recurrent ACLC	Vinorelbine	treatment	2	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT00293345	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma	Gemcitabine Triapine	treatment	1	completed
NCT01258998	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma	No drug interventions	treatment	2	completed
NCT00608361	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Dasatinib	treatment	1	completed
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	AR-42	treatment	1	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT06494371	A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma	No drug interventions	treatment	1	recruiting
NCT01254578	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Lenalidomide	treatment	1	completed
NCT00082888	Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma	Tipifarnib	treatment	2	completed
NCT00117988	17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma	Tanespimycin	treatment	2	completed
NCT00354107	Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma	Brentuximab vedotin Carboplatin Cytarabine Etoposide Hydrocortisone Ifosfamide Methotrexate SGN-30	treatment	1 / 2	terminated
NCT01567709	Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma	Alisertib Vorinostat	treatment	1	completed
NCT00354185	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma	Belinostat Tanespimycin	treatment	1	terminated
NCT01026415	Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)	Brentuximab vedotin Ketoconazole Midazolam Rifampin	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT00131937	Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma	Sorafenib	treatment	2	completed
NCT00001337	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	Rituximab	treatment	2	completed
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Brentuximab vedotin Rituximab	treatment	1 / 2	terminated
NCT01777152	ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas	Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisone Vincristine	treatment	3	completed
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00003970	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma	Irinotecan	treatment	1	completed
NCT00073918	Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclophosphamide Etoposide	treatment	2	completed
NCT00058019	Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	Ixabepilone Patupilone	treatment	2	completed
NCT04526834	Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT02232516	Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma	Lenalidomide Romidepsin	treatment	2	active_not_recruiting
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT01686165	Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL	Belinostat Rituximab	treatment	2	completed
NCT01158274	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	Capecitabine RG-4733	treatment	1	completed
NCT03590574	Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma	No drug interventions	treatment	1 / 2	recruiting
NCT01336920	Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma	Carfilzomib	treatment	1	completed
NCT00199082	Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults	Cyclophosphamide Cytarabine Dexamethasone Doxorubicin Filgrastim Ifosfamide Methotrexate Prednisolone Rituximab Vincristine Vindesine	treatment	4	completed
NCT01657331	Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)	Bendamustine Brentuximab vedotin Pegfilgrastim	treatment	1 / 2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT05377827	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies	WU-CART-007	treatment	1	recruiting
NCT00098891	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Entinostat Isotretinoin	treatment	1	completed
NCT00704691	Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas	Lenalidomide	treatment	0	terminated
NCT03205891	Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas	Brentuximab vedotin Sapanisertib	treatment	1	withdrawn
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01309789	A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms	Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisone Vincristine	treatment	1	completed
NCT02568267	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	Entrectinib	treatment	2	active_not_recruiting
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00697346	Study of MLN8237 in Participants With Advanced Hematological Malignancies	Alisertib	treatment	1	completed
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01466881	Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma	Alisertib	treatment	2	completed
NCT03947255	A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma	Brentuximab vedotin	treatment	2	terminated
NCT01196208	A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001	Brentuximab vedotin	Not Available	Not Available	no_longer_available
NCT01678443	Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	Indium Yttrium Y-90	treatment	1	terminated
NCT01408043	Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	Etoposide Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01950364	A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma	Brentuximab vedotin Rifampin	treatment	1	completed
NCT01075321	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Everolimus Lenalidomide	treatment	1 / 2	completed
NCT01326702	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors	Bendamustine Rituximab Veliparib	treatment	1 / 2	completed
NCT01336933	Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma	Cyclophosphamide Etoposide Pralatrexate Prednisone Sulfate ion Vincristine	treatment	2	completed
NCT01026233	Cardiac Safety Study of Brentuximab Vedotin (SGN-35)	Brentuximab vedotin	treatment	1	completed
NCT00918333	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma	Everolimus Panobinostat	treatment	1 / 2	completed
NCT01793233	Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas	No drug interventions	Not Available	Not Available	completed
NCT05208853	An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma	No drug interventions	treatment	0	unknown_status
NCT01959477	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant	Busulfan Cyclophosphamide Etoposide	treatment	0	completed
NCT00866047	A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma	Brentuximab vedotin	treatment	2	completed
NCT01261247	Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Panobinostat	treatment	2	completed
NCT05907447	A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT00606645	Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma	XmAb 2513	treatment	1	completed
NCT03598998	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	Pembrolizumab Pralatrexate	treatment	1 / 2	active_not_recruiting
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00096005	Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT01449461	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)	Brigatinib	treatment	1 / 2	completed
NCT02465528	Ceritinib Rare Indications Study in ALK+ Tumors	Ceritinib	treatment	2	terminated
NCT00310128	Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma	Cisplatin Cytarabine Etoposide Ibritumomab tiuxetan Methylprednisolone Rituximab	treatment	2	withdrawn
NCT03443128	Vinorelbine for Recurrent ALCL-2017	Vinorelbine	treatment	2	recruiting
NCT01769911	Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma	6-O-benzylguanine Carmustine Cytarabine Etoposide Melphalan	treatment	Not Available	withdrawn
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00499811	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction	Vorinostat	treatment	1	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00089271	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas	Alvespimycin	treatment	1	completed
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00769288	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	No drug interventions	treatment	1	completed
NCT01787409	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency	No drug interventions	treatment	Not Available	recruiting
NCT00947856	A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study	Brentuximab vedotin	treatment	2	completed
NCT00348985	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Belinostat Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT04644315	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors	Alectinib Olive oil	treatment	2	terminated
NCT02652715	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma	No drug interventions	basic_science	Not Available	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT05770037	DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers	Alectinib	treatment	2 / 3	recruiting
NCT03049449	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas	Cyclophosphamide Fludarabine	treatment	1	completed
NCT00601718	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Carboplatin Etoposide Ifosfamide Rituximab Vorinostat	treatment	1 / 2	completed
NCT00801918	Denileukine Diftitox for Relapsed ALCL	Cyclophosphamide Denileukin diftitox Etoposide Ifosfamide	treatment	2	withdrawn
NCT01658319	Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies	Fludarabine Methoxyamine	treatment	1	completed
NCT00004241	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Tanespimycin	treatment	1	completed
NCT00003196	Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	Cyclosporine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT03905135	Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies	Avelumab Interleukin-15, human recombinant	treatment	1	completed
NCT00720135	Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Rituximab	treatment	1	completed
NCT01110135	Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma	Bendamustine Dexamethasone Etoposide Filgrastim	treatment	2	completed
NCT06508463	Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma	Cemiplimab Human interferon beta Ipilimumab Sodium iodide	treatment	1	recruiting
NCT03942263	A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation	No drug interventions	Not Available	Not Available	completed
NCT01769222	Ipilimumab and Local Radiation for Selected Solid Tumors	Ipilimumab	treatment	1	terminated
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT03383965	CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas	No drug interventions	treatment	1	recruiting
NCT00365274	SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma	Brentuximab vedotin Cyclophosphamide Doxorubicin Prednisone SGN-30 Sulfate ion Vincristine	treatment	2	terminated
NCT00278382	Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma	Sorafenib	treatment	2	completed
NCT01943682	Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma	No drug interventions	treatment	1	completed
NCT00458731	Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	Bevacizumab Cediranib	treatment	1	completed
NCT04008394	Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies	No drug interventions	treatment	1	unknown_status
NCT00016094	S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma	Bevacizumab	treatment	2	completed
NCT00005080	506U78 in Treating Patients With Lymphoma	Nelarabine	treatment	2	completed
NCT01129180	Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma	Azacitidine Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT03534180	Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma	Romidepsin Venetoclax	treatment	2	completed
NCT00644189	Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma	Clofarabine	treatment	1 / 2	completed
NCT05106192	Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.	Bexarotene Mechlorethamine Triamcinolone	supportive_care	Not Available	not_yet_recruiting
NCT02168140	CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma	Bendamustine Devimistat Lipoic acid	treatment	1	completed
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00430846	Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies	Brentuximab vedotin	treatment	1	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Lenalidomide Rituximab	treatment	2	terminated
NCT00072514	Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies	Carboplatin Dexamethasone Gemcitabine Rituximab	treatment	2	completed
NCT02939014	Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)	Brentuximab vedotin	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT00079755	Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma	SGN-30	treatment	2	completed
NCT00077155	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma	Cilengitide	treatment	1	completed
NCT05290155	Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies	No drug interventions	treatment	1	recruiting
NCT00112723	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma	Alvocidib	treatment	1 / 2	terminated
NCT05160922	Crizotinib Continuation Clinical Study	Crizotinib	treatment	4	active_not_recruiting
NCT02902874	Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +	No drug interventions	basic_science	Not Available	completed
NCT04021082	CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)	Cerdulatinib	treatment	2 / 3	withdrawn